Trial Profile
A randomized, open-label study of the effect of PEGASYS [peginterferon alfa-2a] plus either amantadine or ribavirin on serum HCV-RNA [hepatitis C virus-RNA] and ALT [alanine aminotransferase] levels/correction in previously untreated patients with chronic hepatitis C viral infection.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jun 2010
Price :
$35
*
At a glance
- Drugs Amantadine (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 25 Jun 2007 Status change
- 08 Jun 2006 New trial record.